Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CD19CAR(2G)-T2A-HER2tG |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
CD19CAR(2G)-T2A-HER2tG comprises CD4+ and CD8+ T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to the intracellular domain of TNFRSF9 (4-1BB), CD3zeta, and a truncated form of ERBB2 (HER2), which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | C174563 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CD19CAR(2G)-T2A-HER2tG | CD19CAR(2G)-T2A-HER2tG | 0 | 0 |
| CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt | CD19CAR(2G)-T2A-HER2tG EGFR806CAR(2G)-EGFRt | 0 | 1 |